Drugs / Tetanus, diphtheria, and acellular pertussis vaccine
Tetanus, diphtheria, and acellular pertussis vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04766086 | Aug 2022 → Apr 2023 | group B streptococcal infection | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus, diphtheria, and acellular pertussis vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04766086 ↗ |
| Modality | Vaccine | “tetanus, diphtheria, and acellular pertussis vaccine (Tdap)” NCT04766086 ↗ |